Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41398-021-01533-1
DC FieldValue
dc.titleAntidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report
dc.contributor.authorBraund, Taylor A.
dc.contributor.authorTillman, Gabriel
dc.contributor.authorPalmer, Donna M.
dc.contributor.authorGordon, Evian
dc.contributor.authorRush, A. John
dc.contributor.authorHarris, Anthony W. F.
dc.date.accessioned2022-10-26T09:02:30Z
dc.date.available2022-10-26T09:02:30Z
dc.date.issued2021-08-04
dc.identifier.citationBraund, Taylor A., Tillman, Gabriel, Palmer, Donna M., Gordon, Evian, Rush, A. John, Harris, Anthony W. F. (2021-08-04). Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report. Translational Psychiatry 11 (1) : 417. ScholarBank@NUS Repository. https://doi.org/10.1038/s41398-021-01533-1
dc.identifier.issn2158-3188
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/233559
dc.description.abstractSide effects to antidepressant medications are common and can impact the prognosis of successful treatment outcome in people with major depressive disorder (MDD). However, few studies have investigated the severity of side effects over the course of treatment and their association with treatment outcome. Here we assessed the severity of side effects and the impact of treatment type and anxiety symptoms over the course of treatment, as well as whether side effects were associated with treatment outcome. Participants were N = 1008 adults with a current diagnosis of single-episode or recurrent, nonpsychotic MDD. Participants were randomised to receive escitalopram, sertraline, or venlafaxine-extended release with equal probability and reassessed at 8 weeks regarding Hamilton Rating Scale Depression (HRSD17) and Quick Inventory of Depressive Symptomatology (QIDS-SR16) remission and response. Severity of side effects were assessed using the Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) scale and assessed at day 4 and weeks 2, 4, 6, and 8. Frequency, intensity, and burden of side effects were greatest at week 2, then only frequency and intensity of side effects gradually decreased up to week 6. Treatment type and anxiety symptoms did not impact the severity of side effects. A greater burden—but not frequency or intensity—of side effects was associated with poorer treatment outcome and as early as 4 days post-treatment. Together, this work provides an informative mapping of the progression of side effects throughout the treatment course and their association with treatment outcome. Importantly, the burden of side effects that are present as early as 4 days post-treatment predicts poorer treatment outcome and should be monitored closely. iSPOT-D: Registry name: ClinicalTrials.gov. Registration number: NCT00693849. © 2021, The Author(s).
dc.publisherSpringer Nature
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceScopus OA2021
dc.typeArticle
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1038/s41398-021-01533-1
dc.description.sourcetitleTranslational Psychiatry
dc.description.volume11
dc.description.issue1
dc.description.page417
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_s41398-021-01533-1.pdf726.37 kBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

8
checked on Feb 3, 2023

Page view(s)

17
checked on Feb 2, 2023

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons